VRTX (STOCKS)
Vertex Pharmaceuticals Inc
$440.050000
+3.780000 (+0.87%)
Prev close: $436.270000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Reshma Kewalramani
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $111,777.58M
- Employees
- 6,100
- P/E (TTM)
- 28.47
- P/B (TTM)
- 5.94
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
13
Strong Buy
20
Buy
6
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$5.03 | $5.17 | -0.1444 | -2.79% |
|
Sep 2025 (Q3)
|
$4.80 | $4.65 | +0.1453 | +3.12% |
|
Jun 2025 (Q2)
|
$4.52 | $4.37 | +0.1507 | +3.45% |
|
Mar 2025 (Q1)
|
$4.06 | $4.37 | -0.3149 | -7.20% |
Financial Statements
| Revenues | $12.00B |
| Benefits Costs and Expenses | $7.36B |
| Cost Of Revenue | $1.65B |
| Costs And Expenses | $7.83B |
| Gross Profit | $10.35B |
| Operating Expenses | $6.18B |
| Selling, General, and Administrative Expenses | $1.75B |
| Other Operating Expenses | $4.42B |
| Operating Income/Loss | $4.17B |
| Income/Loss From Continuing Operations After Tax | $3.95B |
| Income/Loss From Continuing Operations Before Tax | $4.64B |
| Income Tax Expense/Benefit | $690.00M |
| Income Tax Expense/Benefit, Current | $1.20B |
| Income Tax Expense/Benefit, Deferred | -$510.80M |
| Net Income/Loss | $3.95B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $3.95B |
| Net Income/Loss Available To Common Stockholders, Basic | $3.95B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $15.46 |
| Diluted Earnings Per Share | $15.32 |
| Basic Average Shares | 255,700,000 |
| Diluted Average Shares | 258,000,000 |
| Assets | $25.64B |
| Current Assets | $11.20B |
| Inventory | $1.69B |
| Prepaid Expenses | $101.70M |
| Other Current Assets | $9.41B |
| Noncurrent Assets | $14.44B |
| Intangible Assets | $424.20M |
| Other Non-current Assets | $14.02B |
| Liabilities | $6.98B |
| Current Liabilities | $3.86B |
| Accounts Payable | $461.70M |
| Wages | $397.70M |
| Other Current Liabilities | $3.00B |
| Noncurrent Liabilities | $3.12B |
| Equity | $18.67B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $18.67B |
| Liabilities And Equity | $25.64B |
| Net Cash Flow From Operating Activities | $3.63B |
| Net Cash Flow From Operating Activities, Continuing | $3.63B |
| Net Cash Flow From Investing Activities | -$945.40M |
| Net Cash Flow From Investing Activities, Continuing | -$945.40M |
| Net Cash Flow From Financing Activities | -$2.26B |
| Net Cash Flow From Financing Activities, Continuing | -$2.26B |
| Exchange Gains/Losses | $90.90M |
| Net Cash Flow | $515.60M |
| Net Cash Flow, Continuing | $424.70M |
| Comprehensive Income/Loss | $3.81B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $3.81B |
| Other Comprehensive Income/Loss | $3.81B |
| Other Comprehensive Income/Loss Attributable To Parent | -$143.70M |